Beam Therapeutics (BEAM) presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency, ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $28.56, a high estimate of ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Analysts have recently evaluated Keros Therapeutics and provided 12-month price targets. The average target is $28.57, ...

Learn more about whether Corcept Therapeutics Incorporated or Sanofi is a better investment based on AAII's A+ Investor ...

Talat Imran; Chief Executive Officer, Director; Rani Therapeutics Holdings Inc Svai Sanford; Chief Financial Officer; Rani Therapeutics Holdings Inc Welcome to the Rani fourth-quarter and full-year ...

A University of Iowa-led study has revealed the unexpected structure adopted by the DNA repair protein RAD52 as it binds and ...

Research analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Tenaya Therapeutics in ...

Larimar stock is down over 50% this year due to anaphylactic reactions in a study, rising expenses, and cautious market ...

Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...

Learn more about whether CRISPR Therapeutics AG or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Keros plans on engaging with regulatory authorities, starting in the third quarter of 2025. Subject to the outcome of these regulatory interactions, Keros expects to initiate a Phase 2 clinical trial ...